C-GHJXLyGenesis
cell therapy, lymph node bioreactors, organ regeneration
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-GHJX
C-GHJXC-GHJXcell therapy, lymph node bioreactors, organ regeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Emerging Technologies and Aging Research: Bioprinting, Organ Regeneration, and Beyond | AFAR Webinar (March 20, 2025) Innovations in organ and tissue regeneration are rapidly advancing and hold great promise for supporting healthy aging. New therapies can now grow ectopic organs within the body, while 3D‑printing technologies are creating complex, functional tissues from living cells. In this webinar, moderated by AFAR Board Member Sergey Young of the BOLD Longevity Growth Fund, experts Eduardo N. Chini, MD, PhD (Mayo Clinic); Michael Hufford, PhD (LyGenesis); Michael Levin, PhD (Morphoceuticals and Tufts University); and AFAR President Thomas A. Rando, MD, PhD (UCLA) explored how these emerging technologies could transform organ transplantation, drug testing, and regenerative medicine. They also highlighted how new partnerships between academia and biotech may accelerate personalized medicine for all. Learn more about aging research: https://www.afar.org/ Follow AFAR on social med
LyGenesis CEO Michael Hufford joins Prime Movers Lab Partner Gavin Mathis to discuss Michael's extensive background in drug development and the innovative work being done at LyGenesis in regenerative medicine. The company has found a way to turn lymph nodes into bioreactors to grow functioning ectopic organs, particularly the liver. Michael shares insights into their clinical trials, the economic implications of their therapies, and the broader applications of their technology. He also addresses the regulatory landscape and personal reflections on the challenges and future of regenerative medicine.
LyGenesis announced that an initial volunteer has received an injection of donor cells to turn one of their lymph nodes into a second liver. The procedure was carried out in Houston on March 25 as part of a clinical trial that will test the experimental treatment in 12 adults with end-stage liver disease. These patients usually require a liver transplant, but donor organs are in short supply. LyGenesis is hoping to spur the growth of enough healthy liver tissue that patients don’t need a transplant. “We’re using the lymph node as a living bioreactor,” says Michael Hufford, cofounder and CEO of Pittsburgh-based LyGenesis. He says just 10 to 30 percent in additional liver mass could have meaningful effects for patients with end-stage liver disease. About 10,000 people in the United States are on the transplant list for a liver, and many will wait months or years to get one. That number doesn’t include those who need a new liver but don’t qualify for a transplant because of other health
LyGenesis announced that an initial volunteer has received an injection of donor cells to turn one of their lymph nodes into a second liver. The procedure was carried out in Houston on March 25 as part of a clinical trial that will test the experimental treatment in 12 adults with end-stage liver disease. These patients usually require a liver transplant, but donor organs are in short supply. LyGenesis is hoping to spur the growth of enough healthy liver tissue that patients don’t need a transplant. “We’re using the lymph node as a living bioreactor,” says Michael Hufford, cofounder and CEO of Pittsburgh-based LyGenesis. He says just 10 to 30 percent in additional liver mass could have meaningful effects for patients with end-stage liver disease. About 10,000 people in the United States are on the transplant list for a liver, and many will wait months or years to get one. That number doesn’t include those who need a new liver but don’t qualify for a transplant because of other health
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Dr. Michael Hufford, Ph.D. is the Co-Founder and the Chief Executive Officer of LyGenesis ( https://www.lygenesis.com/ ), a clinical-stage cell therapy company that transforms patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs. He also serves as the Interim CEO of Morphoceuticals ( https://www.morphoceuticals.com/ ) a company focused on modifying electric potentials in cells and tissues for a variety of applications in regenerative medicine, from improving amputation stump health and limb regeneration, to organogenesis, to creating a bioelectric atlas where numerous disease indications may be corrected. Dr. Hufford also serves as a scientific advisor to Juvenescence ( https://juvlabs.com/ ) a biotech holding company that develops therapies and products to modify aging and help people live longer. An entrepreneur and drug developer, Dr. Hufford has over 20 years of experience in the development and FDA regulatory approval of small molecules (Cypress
This Phase 2a clinical trial is a dose escalation study of the safety, tolerability, and efficacy of hepatocyte transplantation into lymph nodes via endoscopic ultrasound among subjects with end-stage liver disease.
Talk Title: Prometheus Unbound: From Myth to the Clinical Reality of Organ Regeneration Michael Hufford, CEO and Co-founder of LyGenesis, presents at Investing in the Age of Longevity 2021. In his talk, Michael introduces the cell therapy platform that LyGenesis has developed to solve the critical unmet need for organ transplantation. Explaining how endoscopic ultrasound is being used to help manufacture new organs at low cost, Michael showcases the company's lead programme for patients with end stage liver disease, and demonstrates how the platform can also be leveraged across several disease indications. Download the presentation slides: https://bit.ly/3lewPd3 Investing in the Age of Longevity 2021 was held in London on 17 November 2021. The one-day masterclass brought together scientists and business leaders at the cutting edge of the field, who shared the inside track on the latest aging-related discoveries and investment opportunities. Download the event programme: https://b
Lygenesis, a University of Pittsburgh life sciences spinout, is using cell therapy technology to transform the methodology behind the science of organ transplantation, thanks to experts like Michael Hufford.
Source: https://www.spreaker.com/user/healthcarenowradio/the-incrementalist-grow-your-own-organs- Host Dr. Nick van Terheyden aka Dr. Nick talks Grow Your Own Organs, with Michael Hufford, CEO Lygenesis. The discussion includes using the bodies own bio-reactor (lymph nodes) to grow replacement liver, recent FDA clearance to proceed to human trials, and how one donated liver could mean 70+ patients transplants. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play HealthcareNOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/
2020 was a year of massive disruption for ageing science. On one hand, COVID-19 offered a new paradigm in which to study and explain the benefits of ageing science to investors, healthcare providers and regulators. On the other, two high profile trials didn’t deliver the results that were needed to propel the field into the mainstream. This session looks at what was learned and how to move forward. • Michael Hufford, Co-Founder and CEO, Lygenesis • Maddalena Adorno, Co-Founder and CEO, Dorian Therapeutics • Moderator: Natalia Novac, Senior Director Emerging Technology & Innovation, Lilly New Ventures, Eli Lilly The #Longevity Leaders channel features sessions from the Longevity Leaders Congress, where our mission is to advance innovations that will extend human #healthspan and enable financial, physical and mental #wellness in later life. Sessions feature influential leaders from the worlds of ageing science, consumer products, finance, technology and investment. The events sit
The University of Pittsburgh's Innovation Institute has turned up the volume to connect its innovators to programs, services and funding they need to assess the commercial potential of their innovation or big idea and accelerate on the path to market. Today on Business as Usual, we're talking to Evan Facher Vice Chancellor for Innovation and Entrepreneurship - University of Pittsburgh, and Michael Hufford, CEO and Co-Founder - LyGenesis. Find out how the Innovation Institute helped launch LyGenesis to build an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. It's an amazing story of how our universities are fueling growth and innovation in the Pittsburgh region.
Overview of LyGenesis' technology for organ regeneration.
Innovation 18 at 2017 Innovation Showcase Inventors: Eric Lagasse, PharmD, PhD An estimated 6 million people of the US population are affected by advanced liver diseases. Annually, these diseases result in 100,000 new end-stage liver disease (ESLD) patients, and 40,000 deaths. ESLD patients’ only existing option for survival is liver transplantation, but less than 10% will receive a new liver. LyGenesis enables a patient’s own lymph nodes to be used as bioreactors for liver regeneration. This is a rapid, capital-efficient investment with a final pre-IND large animal study and a completed phase 2a clinical trial with topline data 2.5 years post-funding.
%PDF-1.4 %���� 459 0 obj > endobj xref 459 41 0000000016 00000 n 0000002737 00000 n 0000002884 00000 n 0000002920 00000 n 0000003826 00000 n 0000004577 00000 n 0000005435 00000 n 0000005549 00000 n 0000005740 00000 n 0000006609 00000 n 0000007405 00000 n 0000007498 00000 n 0000008142 00000 n 0000008808 00000 n 0000009006 00000 n 0000009155 00000 n 0000010346 00000 n 0000011610 00000 n 0000012946 00000 n 0000014303 00000 n 0000015635 00000 n 0000016998 00000 n 0000017388 00000 n 0000017502 00000 n 0000017695 00000 n 0000018152 00000 n 0000018638 00000 n 0000019988 00000 n 0000021254 00000 n 000 … dobj 492 0 obj > endobj 493 0 obj > endobj 494 0 obj > endobj 495 0 obj >stream application/postscript CIS_logo Jennifer Gubbin 2017-08-03T13:16:11-05:00 2017-08-03T13:16:11-05:00 2017-08-03T13:16:11-05:00 Adobe Illustrator CS6 (Windows) xmp.iid:1F00F6D37778E711963E9F00DFD6DF3D xmp.did:1F00F6D37778E711963E9F00DFD6DF3D uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:3757DA915178E711963E9F00DFD6DF3D xmp.did:3757DA915178E711963E9F00DFD6DF3D uuid:5D20892493BFDB11914A8590D … 53���k s���U2yw�RW�� y�ڐZ�ꏕk���q���d� t�� endstream endobj 23 0 obj >stream application/postscript facebook_favicon_v2 Laura Ludwig Adobe Illustrator CS5.1 2013-02-11T15:56:12-06:00 2013-02-11T15:56:13-06:00 2013-02-11T15:56:13-06:00 xmp.did:6406E37B7774E211A5D1A606709220BA xmp.iid:6406E37B7774E211A5D1A606709220BA uuid:DB61C8335C02DD11AF6EDFF2834FF873 xmp.iid:B9327CC52B53E1118447BE9FBAC9D66C xmp.did:B9327CC52B53E1118447BE9FBAC9D66C uuid:DB61C8335C02DD11AF6EDFF2834FF873 co … C52B53E1118447BE9FBAC9D66C uuid:DB61C8335C02DD11AF6EDFF2834FF873 converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:B9327CC52B53E1118447BE9FBAC9D66C 2012-02-09T08:39:55-06:00 Adobe Illustrator CS5.1 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:6406E37B7774E211A5D1A606709220BA 2013-02-11T15:56:13-06:00 Adobe Illustrator CS5.1 / converted from application/postscript to application/vnd.adobe.illu … CESS 25 K=5 GRAY PROCESS 12 endstream endobj 24 0 obj > endobj 25 0 obj >stream application/postscript facebook_favicon_v2 Laura Ludwig Adobe Illustrator CS5.1 2013-02-11T15:57:06-06:00 2013-02-11T15:57:08-06:00 2013-02-11T15:57:08-06:00 xmp.did:E98FC1FA9574E211A5D1A606709220BA xmp.iid:E98FC1FA9574E211A5D1A606709220BA uuid:DB61C8335C02DD11AF6EDFF
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Our Pipeline | Lygenesis Skip To Main Content toggle menu Our Pipeline Clinical Development Strategy & Execution We are developing a pipeline of allogeneic cell therapies using the lymph node as an in vivo bioreactor to grow functioning ectopic organs. Discovery Small Animal Large Animal Phase 1 Phase 2 Phase 3 FDA Approval Liver End Stage Liver Disease Phase 2A Thymus Aging POC Completed Kidneys End Stage Renal Disease POC Completed Pancreas Type 1 Diabetes POC Completed Our lead therapy is indicated for patients with End Stage Liver Disease, while our other therapies focus on Type 1 diabetes
ImmuneOnco Biopharmaceuticals (Shanghai) Inc - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Po … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
Lygenesis Skip To Main Content toggle menu Cell Therapies for Life-Threatening Diseases About Our Science Pipeline The Unmet Needs LyGenesis’s cell therapies are targeted at some of the largest unmet needs in medicine, from Type 1 diabetes to end stage liver and renal disease. Our cell therapies completely upend the economics and supply-demand calculus of organ transplantation by using the patient’s own lymph nodes as bioreactors to grow functioning ectopic organs. For our lead liver indication, one donated liver can treat dozens of ESLD patients, and the cell therapy is engrafted into the lym
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
4th Annual Updates in Gastroenterology & Hepatology - Stanford Center for Continuing Medical Education - Continuing Education (CE) <b>A Premier Educational Experience in the Heart of Wine Country</b></p><p>Join us in the beautiful and serene setting of wine country for the<span class="Apple-converted-space">&nbsp;</span><b>4th Annual Updates in Gastroenterology and Hepatology</b>—a dynamic and engaging course designed to bring you the latest advances in the diagnosis and management of gastrointestinal and liver disorders. The program incorporates cutting-e … cutting-edge medical education with the opportunity to unwind amidst vineyards, rolling hills, and exceptional hospitality.</p><p>Tailored for gastroenterologists, hepatologists, primary care physicians, internists, family practitioners, nurse practitioners, physician assistants, and nurses, this comprehensive one-day course offers evidence-based updates in a picturesque, retreat-like atmosphere perfect for learning and professional connection.</p>" /> Family Medicin … Forgot Your Password? Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … cutting-edge medical education with the opportunity to unwind amidst vineyards, rolling hills, and exceptional hospitality. Tailored for gastroenterologists, hepatologists, primary care physicians, internists, family practitioners, nurse practitioners, physician assistants, and nurses, this comprehensive one-day course offers evidence-based updates in a picturesque, retreat-like atmosphere perfect for learning and professional connection. Registration Early Bird Registration … is activity. Complete the STAP Reimbursement Request Form and submit to your department administrator. Credits AMA PRA Category 1 Credits™ (19.00 hours), AAPA Category 1 CME credits (19.00 hours), ANCC Contact Hours (19.00 hours), CA BRN - California Board of Registered Nurses Contact Hours (19.00 hours), Non-Physician Par
Longevity Investors Investing in Anti-Aging Biotech Startups Blog Fundraising Due diligence Data room M&A Startups Log in Get demo Start a trial Blog / Fundraising Longevity investors investing in anti-aging biotech in 2026 9 December 2025 · 14 min read Author Ellty editorial team Longevity went from fringe science to serious biotech in three years. Most investors still confuse healthspan extension with wellness apps. The ones on this list actually funded companies through Phase 2 trials and understand the difference between rapamycin analogs and NAD+ supplements. Quick list Longevity Visi … nce between rapamycin analogs and NAD+ supplements. Quick list Longevity Vision Fund : Led Altos Labs' $3B raise for cellular reprogramming in 2024. Khosla Ventures : Backed NewLimit's $105M Series A for epigenetic reprogramming in 2025. Andreessen Horowitz : Led Loyal's $58M Series B for dog aging drugs in 2024. Juvenescence : Invested $45M in Cleara Biotech for senescent cell clearance in 2025. Apollo Health Ventures : Backed Shift Bioscience's $23M Series A … acked Selphagy's $18M Series A for autophagy enhancement in 2025. Longevity Fund : Led Repair Biotechnologies' $12M Series A for thymus regeneration in 2024. 8VC : Invested $90M in Retro Biosciences for autophagy and plasma therapies in 2025. Methuselah Fund : Backed LyGenesis' $100M Series B for organ regeneration in 2024. Kizoo Technology Capital : Led Oisin Biotechnologies' $20M Series A for senolytic gene therapy in 2025. Jim Mellon's Juvenescence : In … Cradle Genomics' $22M Series A for induced tissue regeneration in 2025. OS Fund : Invested in Oisin Biotechnologies' senolytic platform development in 2024. Picking investors who understand longevity science Experience : Find investors who've backed biotech through clinical trials, not just preclinical hype. Ask their portfolio companies about support during Phase 2 failures. Most longevity startups pivot their lead indication three times before finding something … nize due diligence : Set up an Ellty data room with your animal study data, IND application drafts, and scientific publications before they ask. It speeds up the process when they want their scientific advisors to review your mechanism. Set up introductory meetings : Lead with your efficacy data in animal models and your FDA strategy. Don't w
Amazing week/month for several of my portfolio companies: meaningful regulatory/clinical advancement, X-prize recognition, or funding, with a surprising density of good news just this week... I'm… | Karl R. Pfleger LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices … everal of my portfolio companies: meaningful regulatory/clinical advancement, X-prize recognition, or funding, with a surprising density of good news just this week... I'm now firmly (not just weakly) a clinical stage biotech investor. Though my portfolio is still mostly preclinical companies, 3 companies have recently become clinical stage (2 just announced this week), pushing my clinical-stage portfolio total to 5. Juvena this week announced phase 1 start: https://lnkd.in/d … 3 of my portfolio companies were recognized as finalists at this stage of the X-Prize rejuvenation competition: the aforementioned Immunis (named a top40 team) & Cyclarity, plus also Deciduous. Amazing week+. Juvena Therapeutics 10,423 followers 1y Exciting news from Juvena Therapeutics! We’re proud to announce our transition to a clinical-stage company, marking a significant step forward in our mission to transform people’s lives with tissue-restorative therapeutics. Our
Longevity Vision Fund Company Overview, Contact Details & Competitors | LeadIQ Learn more at LeadIQ.com Start free Insights Similar companies Tech Stack Media & News Email Format FAQ Insights Niche Investment Focus Longevity Vision Fund specializes in funding innovative health tech, longevity, and biotech companies that are developing groundbreaking therapeutic, diagnostic, and AI-driven healthcare solutions. This focus presents opportunities to introduce products and services tailored to the unique needs of early-stage biotech and health technology ventures. Growth and Expansion With … sion With recent investments such as the $4 million funding into LyGenesis, the fund is actively expanding its portfolio in organ regeneration and biotech innovations. Sales efforts could target portfolio companies looking for supporting technologies like lab equipment, clinical research tools, or specialized AI applications. Emerging Market Players As a venture fund with a small team of 2-10 employees, LVF is likely seeking strategic partnerships and external vendors to comp … longevity and preventive medicine themes. Similar companies to Longevity Vision Fund Calico $100M $250M Oisin Biotechnologies $1M $10M Insilico Medicine $1B $10B Rejuvenate Bio $10M $25M resTORbio $1M BioAge Labs $25M $50M UNITY Biotechnology $10M $25M Life Biosciences $10M $25M Explore similar companies Longevity Vision Fund Tech Stack Longevity Vision Fund uses 1 technology products and services including YouTube, and more. Explore Longevity Vision Fund 's tech stack be … ate financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Oct 21, 2019 | www.prnewswire.com Longevity Vision Fund 's Email Address Formats Longevity Vision Fund uses at least 1 format(s): Longevity Vision Fund Email Formats Example Percentage [email protected] [email protected] 90% [email protected] [email protected] 10% See more formats Frequently Asked Questions Where is Longevity Vision Fund 's headquarters located? Longevity Vision Fund 's main headquarters … es across 2 continents, including North America Asia . What is Longevity Vision Fund 's official website and social media links? Longevity Vision Fund 's official website is lvf.vc and has social profiles on LinkedIn . What is Longevity Vision Fund 's NAICS code ? Longevity Vision Fund 's NAICS code is 52391 - Miscellaneous Interm
The Prototype: This Startup Aims To Grow New Mini-Organs In Patients Sign Up For Newsletters Games Share a News Tip Featured Featured Breaking News White House Watch Daily Cover Stories Making It Their Way: Six TikTok Creators On Finding A High-Quality Content Strategy That Pays Off | Paid Program The Hidden Tax On Enterprise AI: 1 In 5 Workers Lose A Full Day Every Week | Paid Program Silicon & Steel Editorial Video Series Turning Pressure Into Progress For Your Small Business | Paid Program Uniting To Advance Blood Cancer Research | Paid Program The Enterprise AI Shortcut: Why Co-Innovat … where I looked at how AI threatens the security of IT systems, a million-dollar prize for finding a WhatsApp bug, and more. SCIENCE AND TECH TIDBITS Does infinity exist? Scientific American profiles a branch of mathematics that is based on the idea that infinity is impossible, since the universe itself is finite. This is tough to implement in practice, because a lot of advanced mathematics revolves around sets of infinite numbers. However, some are hopeful that this math coul
Our Pipeline - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Our Pipeline CORE MEDICINES PIPELINE Leading Healthspan Innovations Our core medicines (JuvTherapeutics) are comprised of therapeutics developed by the Juvenescence team, targeting fundamental aging mechanisms with a near-term age-related first indication identified for clinical development. PAI-1 Inhibitor GDF-15 mAb CD38 Inhibitor Ketone Rx Plasmalogen PORTFOLIO COMPANIES Our portfolio companies represent strategic investments across a diverse array of technologies focused on increasing healthy lifespan
Juvenescence VC Portfolio Companies & Investment Focus | InvestorMatch.pro Investor Match How It Works Pricing Explore Investors For Investors Blog About VC Firms Juvenescence VC JU Juvenescence VC Douglas, Isle of Man Website How to approach: warm intro preferred Start a Campaign Explore Similar Investors Stage series-a+ Check Size $5.0M – $20.0M Portfolio 2+ companies Team 5 partners Investor activity Investments in last 12 months: 0 Investment Thesis Focused on extending healthy human lifespans via biotech, pharmaceuticals, and disruptive drug discovery. Meet the Team DG Dr. Greg Bailey … VC Firms BE Beyond Longevity Ventures Pre-Seed · Seed · Austin, TX LO Longevity Fund Pre-Seed · Seed · Palo Alto, CA RA RA Capital Management Seed · Pre-Seed · Boston, MA AP Apollo Health Ventures series-a+ · Growth · Berlin, Germany VE VenBio Partners Pre-Seed · Growth · San Francisco, CA AP Apex Longevity Ventures seed+ · Series A · San Francisco, CA Browse More Investors series-a+ Investors All VC Firms Frequently Asked Questions What does Juvenescence VC invest in? What s
LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease | Lygenesis Skip To Main Content toggle menu Investors & Media Company Overview View All LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder. Press
LyGenesis CEO Discusses Transforming Organ Transplant Experience at Forbes Summit | Pittsburgh Life Sciences Alliance posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By … Cell: Link Cell Therapies launched Monday with a $60 million Series A round to fund the creation of the next wave of CAR-T therapies. The startup plans to go after the treatment of solid tumors, where ... #lucidquest #genetherapy #celltherapy J&J backs financing round for Stanford CAR-T cell therapy spinout Link Cell endpoints.news Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in LucidQuest 7,489 followers 6mo Report this post LucidQuest Stra … Cell: Link Cell Therapies launched Monday with a $60 million Series A round to fund the creation of the next wave of CAR-T therapies. The startup plans to go after the treatment of solid tumors, where ... #lucidquest #genetherapy #celltherapy J&J backs financing round for Stanford CAR-T cell therapy spinout Link Cell endpoints.news Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 3,805 followers View Profile Follow Explore related topics Inno
Growing Livers In Lymph Nodes A Lesson On Working With Nature Get more Cell & Gene insight with our FREE newsletter sign me up Log In or Subscribe Explore CGT Production Vectors Cell Therapy Manufacturing Gene Therapy Manufacturing Formulation Fill-Finish Cold Chain Management Quality Control & Assurance Find Suppliers Clinical Trial Services Manufacturing Regulatory Supply Chain Outsourcing Translational Research Watch Now STREAM Video Channel Cell & Gene Live Cell & Gene: The Podcast Cell & Gene Tech Expo Our Communities Advancing RNA Bioprocess Online Clinical Leader Cli
Eric Lagasse - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Eric Lagasse Chief Scientific Officer at LyGenesis Inc. Eric Lagasse 's Executive Work History Current Chief Scientific Officer , Chief Scientific Officer Equilar on 03/07/2026 LyGenesis Inc. Past To view Eric Lagasse's complete executive work history, sig … m the Biozentrum, University of Basel, Switzerland. He completed a postdoctoral fellowship at Stanford University in the School of Medicine before accepting a position of Assistant Professor at the University of Pittsburgh School of Medicine. Dr. Lagasse is the author of more than 60 peer-reviewed publications in addition to reviews and book chapters. His work has been cited over 11,000 times with issued and pending patents. Source: LyGenesis Inc. on 03/07/2026 Eric Lagasse ' … m the Biozentrum, University of Basel, Switzerland. He completed a postdoctoral fellowship at Stanford University in the School of Medicine before accepting a position of Assistant Professor at the University of Pittsburgh School of Medicine. Dr. Lagasse is the author of more than 60 peer-reviewed publications in addition to reviews and book chapters. His work has been cited over 11,000 times with issued and pending patents. Source: LyGenesis Inc. on 03/07/2026 Eric Lagasse '
Work of Dr. Eric Lagasse Highlighted in Forbes – Regenerative Medicine at the McGowan Institute Skip to content Search for: PITT HEALTH SCIENCES UPMC Search for: Toggle Navigation Home About Us Welcome Mission, Vision, and Overview What Is Regenerative Medicine? Faculty/Sr. Staff Bios Executive Committee Leadership Staff Contact Us Clinical Site Our Research Programs McGowan Partnerships Laboratories Find Clinical Trials Research Pillars Matrix Our Technologies Professional Development Seminar Series Admissions Career Opportunities Student Training Opportunities Wiegand Summer Internship … s Sergey Young, a Forbes Council Member and the founder of the Longevity Vision Fund, recently published in Forbes the article entitled, “Will You Live to 200? Five Levels of Breakthroughs in Longevity Research You Must Know About.” Of the five major levels of biological organization (cell, tissue, organ, organ system, and organism), one of his highlighted breakthroughs included the work of McGowan Institute for Regenerative Medicine faculty member Eric Lagasse, PharmD, PhD , … any, whose investors include Juvenescence and my organization, Longevity Vision Fund, also has plans for kidney, pancreas, and thymus regeneration. LyGenesis’ achievements are a crucial step toward whole organ regeneration that could, along with other upcoming technologies, allow us to live to 200 (or at least beyond the commonly accepted maximum of 120 years). Read more… Forbes The McGowan Institute For Regenerative Medicine 2022-07-14T14:44:55+00:00 May 5, 2021 | Awar
About Us | Lygenesis Skip To Main Content toggle menu About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs. Instead of one donor organ treating one patient, LyGenesis’ technology enables one donor organ to treat dozens of patients. Instead of major surgery, LyGenesis uses outpatient endoscopic ultrasound for transplantation of its cell therapy, which enables cells to engraft, proliferate, and become a functioning ectopic organ. LyGenes … m the Biozentrum, University of Basel, Switzerland. He completed a postdoctoral fellowship at Stanford University in the School of Medicine before accepting a position of Assistant Professor at the University of Pittsburgh School of Medicine. Dr. Lagasse is the author of more than 60 peer-reviewed publications in addition to reviews and book chapters. His work has been cited over 11,000 times with issued and pending patents. Cell Therapies for Life-Threatening Diseases About
About Us | Lygenesis Skip To Main Content toggle menu About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs. Instead of one donor organ treating one patient, LyGenesis’ technology enables one donor organ to treat dozens of patients. Instead of major surgery, LyGenesis uses outpatient endoscopic ultrasound for transplantation of its cell therapy, which enables cells to engraft, proliferate, and become a functioning ectopic organ. LyGenes
About Us | Lygenesis Skip To Main Content toggle menu About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs. Instead of one donor organ treating one patient, LyGenesis’ technology enables one donor organ to treat dozens of patients. Instead of major surgery, LyGenesis uses outpatient endoscopic ultrasound for transplantation of its cell therapy, which enables cells to engraft, proliferate, and become a functioning ectopic organ. LyGenes … losophy, Politics and Economics, he worked in Asia and the United States in two fund management companies, GT and Thornton, before establishing his own business in 1991. This business continues today, but Jim no longer works as a fund manager and is, instead, focused on biotech, clean food, and property, with other business interests managed by his family office, the Burnbrae Group. These interests include banking, mining, and hotels. Jim is Chairman and co-founder of Juvenes
LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease | Shannon Hayes, CCRP LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept
About Us | Lygenesis Skip To Main Content toggle menu About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs. Instead of one donor organ treating one patient, LyGenesis’ technology enables one donor organ to treat dozens of patients. Instead of major surgery, LyGenesis uses outpatient endoscopic ultrasound for transplantation of its cell therapy, which enables cells to engraft, proliferate, and become a functioning ectopic organ. LyGenes
About Us | Lygenesis Skip To Main Content toggle menu About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs. Instead of one donor organ treating one patient, LyGenesis’ technology enables one donor organ to treat dozens of patients. Instead of major surgery, LyGenesis uses outpatient endoscopic ultrasound for transplantation of its cell therapy, which enables cells to engraft, proliferate, and become a functioning ectopic organ. LyGenes … ogy from the University of Pittsburgh before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School. He is an award-winning lecturer, and the author of more than 100 scientific publications, presentations, and OpEds, with multiple issued and pending patents. Cell Therapies for Life-Threatening Diseases About Our Science Pipeline Investors & Media Contact Copyright Lygenesis © 2026. Privacy Policy.
About Us | Lygenesis Skip To Main Content toggle menu About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs. Instead of one donor organ treating one patient, LyGenesis’ technology enables one donor organ to treat dozens of patients. Instead of major surgery, LyGenesis uses outpatient endoscopic ultrasound for transplantation of its cell therapy, which enables cells to engraft, proliferate, and become a functioning ectopic organ. LyGenes
News - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us News In the News Juv on the Road Press Releases Publications Videos All Press Releases Juvenescence Completes Phase 1 Trial of PAI-1 Inhibitor February 26, 2026 Press Releases Juvenescence Appoints Eileen Jennings-Brown as CTO and Strengthens UAE Presence in Masdar City’s Life Science Innovation Cluster February 16, 2026 Videos Listen in to the interview to hear our co-founder Dr. Greg Bailey discussing Juvenescence strategy February 5, 2026 Juv on the Road Eric Verdin, our collaborator in the Buck institut
Hepatocyte Transplantation into Lymph Nodes: A Novel Approach to End-Stage Liver Disease (VIDEO) Houston Methodist Main Site Leading Medicine Academic Institute Leading Medicine International Patients Leading Medicine Giving Leading Medicine Careers Leading Medicine Leading Medicine Houston Methodist Main Site Research Areas Research Areas Digital Health Solutions Gastroenterology & GI Surgery Heart & Vascular Infectious Disease Neurology & Neurosurgery Obstetrics & Gynecology Oncology Ophthalmology Organ Transplant Orthopedics & Sports Medicine Otolaryngology Quality & … opy Print Topics Transplant Gastroenterology Did you find this article helpful? Submit Thank you for your feedback. Categories Clinical Innovation Knowledge Expansion Physician and Academic Leaders Research Popular Topics TAVR Stroke Sports Medicine Immunotherapy COVID-19 Resources Methodology: Research & Education News Houston Methodist MD Twitter DeBakey CV Education YouTube DeBakey Cardiovascular Journal Services & Specialties Heart & Vascular Neurology & N … rgery Transplant Get Updates from Houston Methodist Please enter a valid email. Submit Stay Connected Giving With your support, Houston Methodist provides exceptional research, education and care that is truly leading medicine. Donate Houston Methodist Main Site Academic Institute International Patients Careers Education Education Areas CME & Professionals GME & Residencies Research Education Alumni Association Research Areas of Research Core Facilities Clinical Trial
Follow the Money: Sepsis Diagnostic Test, Expanding Cardiovascular Disease Info, Oncology, Peptide Therapeutics, CRISPR Subscribe News Latest News Post a Press Release View Press Releases Submit a Story Reprint Articles Advertise Media Kit Digital Advertising Opportunities Lead Generation Whitepapers Webinars Podcasts Editorial Calendar Free Downloads Whitepapers Podcasts Webinars Inside Ebooks Events Webinars Industry Events Dx Conferences Tri-Conference Next Generation Dx Dx Innovation Summit About Editorial Profile Editorial Calendar Contact Next Generation Dx Su … he round, with participation from Essential Capital, Stray Dog Capital, iSelect Fund, and existing major investor The Production Board. $16M: Series A for Cell-Free DNA Platform Aqtual has raised $16 million in Series A financing, co-led by Genoa Ventures, Manta Ray Ventures, and Yu Galaxy. Aqtual's proprietary platform evaluates protein regulation, epigenetics, and transcriptomics by analyzing previously unexplored cell-free DNA fragments found in blood, opening … has received a $10 million investment from Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures. As a spinoff from Intermountain Health, Culmination Bio maintains exclusive rights to a physical library and cloud-based data lake covering over 40 years of de-identified patient electronic health records and biospecimen data. As the most extensive data lake of its kind, it enables biopharmaceutical companies to gain important insights criti … leading private equity investor Russell Carson’s CS Venture Opportunities Fund. The funding will be used to advance its first therapeutic candidate in oncology, nominate a second development candidate, and advance multiple internal and partnered discovery programs. Flashpoint will also use the funds to expand its team and enhance the platform to develop best-in-class multi-targeted RNA, CRISPR, and peptide therapeutics with unique characteristics. $9M: Funding for Medic … velopment program. The investment round was led by Boehringer Ingelheim Venture Fund and Scottish Enterprise. Leveraging the power of bacteriocins, Glox Therapeutics aims to advance the field of antimicrobial therapy by overcoming resistance to traditional antibiotics. It will focus on selectively eradicating target pathogens while preserving the
University of Pittsburgh Archives - I-Corps Hub: Interior Northeast About Who We Are Leadership Faculty Leads Operations Group Instructors Programs Regional I-Corps Courses NSF I-Corps Teams Regional Instructor Training Technology Scouting NASA I-Corps Conference Courses Events Partners Binghamton University Cornell University Dartmouth College RIT Syracuse University University at Buffalo University of Pittsburgh University of Rochester University of Vermont West Virginia University News University of Pittsburgh March 17, 2026 $45M Raised, 114 New Jobs Created: I-Corps Startups Accelerate Dee … gh headquarters. read more December 20, 2023 Astria Biosciences Wins $275K SBIR Award Astria Biosciences Wins $275K SBIR Award https://www.in-icorps.org/wp-content/uploads/2023/12/Picture1.jpg 936 702 I-Corps Hub: Interior Northeast I-Corps Hub: Interior Northeast https://www.in-icorps.org/wp-content/uploads/2023/12/Picture1.jpg December 20, 2023 March 27, 2024 Astria Biosciences, which spun out of research conducted at the University of Pittsburgh, is developing the first si … onal Science Foundation has awarded Cornell University a $15 million, five-year grant to lead the newest Innovation Corps Hub, I-Corps: Interior Northeast Region. read more [email protected] 222 Day Hall Ithaca, NY 14853 This program is administered by the Center for Regional Economic Advancement , a division of Cornell Research & Innovation. Sign up for news LinkedIn YouTube About Who We Are Leadership Faculty Leads Operations Group Instructors Programs Regional I-C
Sell or Invest in LyGenesis Stock Pre-IPO Products Our Products Liquidity Solutions Tender offers and liquidity programs Investment Platform Buy and sell private company stock Data & Intelligence Private market pricing and valuations products Settlement Patented Private share transfer technology Capital Solutions Primary raises and fund structures WealthConnect Equity-specific tax and wealth advice Buy and Sell Pre-IPO Stock Trade private company shares with vetted buyers and sellers on a regulated marketplace. Sign Up Log In Use Cases Use Cases Employees & Shareholders Sell vested eq
LyGenesis Raises $19M in Series A-2 Funding Led by Prime Movers Lab Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Ga … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
7 VCs Funding Longevity Startups in 2026 Contact us News & Insights Cure Innovation Index Healthcare News Investment Founder Stories Cure Original Reports Cure Conversations Racing to Cures: The Cure U.S.-China Biotech Competitiveness Scorecard June 22, 2026 What Makes an Institution Innovative? A Cure Original Report April 29, 2026 Apply for Membership Work in NYC Join Now Cure Residents People of Cure Your Home in NYC Members can access hotdesking, private conference rooms, event space, a cafe, and a gym—all within a healthcare focused environment. Learn More Learn More Attend An Event A … n Holding Stage focus : Seed through Series B, plus their BOLD Longevity Growth Fund Check size range : $1M–$10M; BOLD makes larger growth checks Healthcare focus : Cellular reprogramming, AI in healthcare, regenerative medicine, preventive diagnostics, and organ regeneration Geographic focus : Global, with a presence across the US, Europe, and Asia Assets under management : Over $2 billion Currently deploying : Yes Notable healthcare portfolio companies : Insilico Medicine - … echnology, preventative medicine, and AI in healthcare. The company's BOLD fund, founded with Peter Diamandis in 2023, focuses on growth-stage startups. Longevity Vision Holding was also an investor in unicorn, Freenome. 4. LongeVC Stage focus : Pre-seed through seed Check size range : $500K–$5M Healthcare focus : longevity biotechnology, aging biomarkers, AI-driven drug discovery, regenerative and preventative medicine, and platform technologies that support longevity t … C manages a portfolio of more than 25 companies, and is deploying $120 million (Fund II) . 5. age1 Stage focus : Pre-Seed, Seed, and early Series A Check size range : $500K–$4M Healthcare focus : Age-related disease therapeutics, senolytics, longevity biomarkers, and healthspan biology Geographic focus : U.S. first, with selective Europe presence Assets under management : $35 million Currently deploying : Yes Notable healthcare portfolio companies : Loyal - canine longevity d … , Germany; invests across Europe and the U.S. Assets under management : Current fund size is €300M Currently deploying : Yes Notable healthcare portfolio companies : Reservoir Neuroscience - vascular aging therapy Elevian - regenerative longevity medicine Cellvie - mitochondrial therapy Established in 2000 and based in Karlsruhe, Germany, Kizoo T
LyGenesis Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies LyGenesis Teams LyGenesis Save Saved Pittsburgh 6 Total Employees View Website Overview Jobs Offices Is This Your Company? Claim Profile Healthtech Biotech LyGenesis is an organ regeneration company. LyGenesis Offices OnSite Workspace Employees work from physical offices. Typical time on-site: Pittsburgh, Pennsylvania, USA Companies Jobs Tracker Articles More Join Log In Tech Jobs Companies Articles Remote Best Places To
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
%PDF-1.7 4 0 obj (Identity) endobj 5 0 obj (Adobe) endobj 8 0 obj > stream x��| ��7>�������.�tE]'�ҩ�-ɖ% $۲e���16S �� J$�!H�lp��0!�C �G 8!�Ġ���Ν$W ��������sߝٙٙ�y�gfwO#� �š����M�o��D���!d l����_� ���x�������_oC���BuS}C����!៛ڦuL��7�D܃C�}������� ^���"��5�#Zp��� �0�G���[�.�) �� �w��uk\�Ot}��u�C}W,Z�x��ޯ}�k���[�����[(�^|��E��V#t3�?gꒅ��k��K�~(�J�@��Iۯ �A�%��lx�l��1I��>|��U��o! �.�]s��������w=?kټ +� 09� ��)gR?s2��ye�����^ߙ�;Y8��.�a,M4�Ս?G�A���i �%�"��)�s�������c�e���� >6�y��yE�FF�ѯ�kH AE;���:?�}߈����� _'?� *� �1��r�T�_E��y� M=^�fr磙̿�>E��:��Q%>�l���U����
Collaboration Deals in Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Network FA … The Jackson Laboratory The Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center The Native Antigen Company The New York Stem Cell Foundation The Parker Institute For Cancer Immunotherapy Theragen Theragent TheraPanacea Theriva Biologics Thermo Fisher Scientific ThinkCyte ThirdEye Tianjin CanSino Biotechnology Tianjin University Tiba Biotech TiumBio Tivic Health Systems T Med TMG - Tropical Melhoramento e Genética Today TCI Tolo Biotech Tome … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … nology Related Reports Biotechnology Market Report by Product Type, Technology, Application, and Region 2026-2034  Report 138 Pages April 2026 Global From €3609 EUR $3,999 USD £3,129 GBP Biotechnology Market in the US 2025-2029  Report 170 Pages January 2025 United States From €2256 EUR $2,500 USD £1,956 GBP North America Biotechnology Market Report by Product Type, Technology, Application, Countries and Company Analysis 2025-2033  Report 200 Pages Sep … on Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
News - I-Corps Hub: Interior Northeast About Who We Are Leadership Faculty Leads Operations Group Instructors Programs Regional I-Corps Courses NSF I-Corps Teams Regional Instructor Training Technology Scouting NASA I-Corps Conference Courses Events Partners Binghamton University Cornell University Dartmouth College RIT Syracuse University University at Buffalo University of Pittsburgh University of Rochester University of Vermont West Virginia University News News Wildfire Technology Researchers Participate in a NASA I-Corps Pilot Taught by the IN Hub https://www.in-icorps.org/wp-content/uplo … onal course hosted by the Interior Northeast I-Corps Hub. Soctera wins $1M SBIR Award for Semiconductor Innovation https://www.in-icorps.org/wp-content/uploads/2024/05/2020_1226_002.png 6381 3589 I-Corps Hub: Interior Northeast I-Corps Hub: Interior Northeast https://www.in-icorps.org/wp-content/uploads/2024/05/2020_1226_002.png May 2, 2024 May 6, 2024 icorpshubstg May 2, 2024 No Comments Soctera wins $1M SBIR Award for Semiconductor Innovation The SBIR award supports the com … rural areas through reduced costs. Verde Technologies Receives Liftoff Contest Award to Develop Flexible Solar Energy Modules https://www.in-icorps.org/wp-content/uploads/2024/04/AdobeStock_175556195-scaled.jpeg 2560 1707 I-Corps Hub: Interior Northeast I-Corps Hub: Interior Northeast https://www.in-icorps.org/wp-content/uploads/2024/04/AdobeStock_175556195-scaled.jpeg April 19, 2024 May 6, 2024 icorpshubstg April 19, 2024 No Comments Verde Technologies Receives Liftoff Cont … pshubstg April 19, 2024 No Comments Verde Technologies Receives Liftoff Contest Award to Develop Flexible Solar Energy Modules Verde Technologies, a 2021 I-Corps alumni company from the University of Vermont, is developing a lightweight and flexible way to capture solar energy using perovskite. Sostos Hits Milestones for Cancer Treatment AI Technology https://www.in-icorps.org/wp-content/uploads/2024/04/warren-umoh-qycBqByWIY-unsplash-scaled.jpg 2560 1440 I-Corps Hub: Interio … ncer treatment optimization, recently secured two SBIR Phase I grants — a $275K award from the National Science Foundation (NSF) and a $400K award from the National Cancer Institute (NCI). Carbon To Stone Receives $600K+ to Advance Innovative Carbon Management Technology https://www.in-icorps.org/wp-content/uploads/2024/03/2023_1003_RY_00318-Larg
Lygenesis Raises $37 Million, Creates 6 Local Jobs - I-Corps Hub: Interior Northeast About Who We Are Leadership Faculty Leads Operations Group Instructors Programs Regional I-Corps Courses NSF I-Corps Teams Regional Instructor Training Technology Scouting NASA I-Corps Conference Courses Events Partners Binghamton University Cornell University Dartmouth College RIT Syracuse University University at Buffalo University of Pittsburgh University of Rochester University of Vermont West Virginia University News I-Corps Alumni University of Pittsburgh Lygenesis Raises $37 Million, Creates 6 Local Job … ar Startup Raises Over $17M Buffalo AI Startup Secures $1 Million STTR Phase II Grant [email protected] 222 Day Hall Ithaca, NY 14853 This program is administered by the Center for Regional Economic Advancement , a division of Cornell Research & Innovation. Sign up for news LinkedIn YouTube About Who We Are Leadership Faculty Leads Operations Group Instructors Programs Regional I-Corps Courses NSF I-Corps Teams Regional Instructor Training Technology Scouting NASA I-
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company | Organovo Holdings, Inc. | Fabrice PIU | 22 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Con
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders LyGenesis: Funding, Team & Investors | Startup Intros Home / Organizations / LyGenesis § Pri
Growing New Livers to Save Lives - What's Your Problem? | iHeart Your Library Podcasts News All Episodes Growing New Livers to Save Lives March 19, 2026 • 40 mins Michael Hufford is the co-founder and CEO of LyGenesis, a company working on a new treatment for end stage liver disease. Michael’s problem is this: How do grow a new liver inside the body of a sick patient? In this episode, Michael explains: The liver's unique power of regeneration The organ transplant crisis and how regeneration can help The science behind using lymph nodes to grow new organs The status of Ly
Drs. Kacey Marra and Eric Lagasse Recognized During Pitt’s Celebration of Innovation – Regenerative Medicine at the McGowan Institute Skip to content Search for: PITT HEALTH SCIENCES UPMC Search for: Toggle Navigation Home About Us Welcome Mission, Vision, and Overview What Is Regenerative Medicine? Faculty/Sr. Staff Bios Executive Committee Leadership Staff Contact Us Clinical Site Our Research Programs McGowan Partnerships Laboratories Find Clinical Trials Research Pillars Matrix Our Technologies Professional Development Seminar Series Admissions Career Opportunities Student Training O … Chair of Research for the Department of Plastic Surgery The Emerging Innovator Award is presented to an early-to-mid career Pitt faculty member who has worked towards achieving impact for their research through commercial translation, and a dedication to mentoring the next generation of innovators and entrepreneurs. Dr. Marra is a pioneering innovator around the problem of repairing large gap nerve injuries. She was inspired in this work after receiving funding from the Depa … to restore up to 80 percent of nerve function in large-gap injuries through the application of a biodegradable tube containing a time-released protein growth factor. During her time at the Pitt, she has submitted 23 invention disclosures to the Innovation Institute, has been issued six patents on her discoveries, and has had her innovations licensed six times, including the formation of three startup companies. This puts her in the top handful of women innovators in the unive … d and preparing to hire a CEO to help the company take its next steps toward an application to the Food and Drug Administration to conduct clinical trials. Watch the award presentation here . Startup of the Year LyGenesis Co-Founder: Eric Lagasse, PharmD, PhD (pictured bottom), Associate Professor in the Department of Pathology, University of Pittsburgh, with a secondary appointment in Pitt’s Clinical and Translational Institute For over a decade, Dr. Lagasse has been researc … orhood and is poised for incredible growth, right here in Pittsburgh. Watch the award presentation here . “Universities are places where new knowledge is developed and disseminated. At Pitt, our faculty and students are passionate about translating new knowledge into new products and services and companies that make an impact on the world and our
LyGenesis Announces a New Peer-Reviewed Publication Expanding its Liver Regeneration Technology - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development LyGenesis Announces a New Peer-Reviewed Publication Expanding its Liver Regeneration Technology January 20, 2022 | 2 min read Twitter LinkedIn Facebook Email Print LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, Ty … ism. Privately held with investment support from Juvenescence, Longevity Vision Fund, and other investors, LyGenesis is headquartered in Pittsburgh, Pennsylvania . To learn more, please visit lygenesis.com . Contact Information Media contact: Jacqueline Jeha, MPH +1.401.374.0955 [email protected] View original content: https://www.prnewswire.com/news-releases/lygenesis-announces-a-new-peer-reviewed-publication-expanding-its-liver-regeneration-technology-301464 … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Data and Safety Monitoring Board Approves LyGenesis's Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Data and Safety Monitoring Board Approves LyGenesis’s Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration March 5, 2025 | 5 min read Twitter LinkedIn Facebook Email Print The next four patients will receive a higher dose of LyGenesis's cell therapy to grow functionin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
This company is about to grow new organs in a person for the first time | MIT Technology Review You need to enable JavaScript to view this site. Skip to Content MIT Technology Review Featured Topics Newsletters Events Audio MIT Technology Review Featured Topics Newsletters Events Audio Biotechnology and health This company is about to grow new organs in a person for the first time A volunteer with severe liver disease will soon undergo a procedure that could lead them to grow a second liver. By Jessica Hamzelou archive page August 25, 2022 Ms Tech | Envato In the coming weeks, a volunteer in B
Calaméo - Jims No 04 June 2023 Features Personalization Transform your documents into captivating experiences Integrations Connect Calaméo to your favorite applications Studio Make publications that look like you Conversion Generate valuable leads from your publications Multi-Accounts Manage multiple accounts with the Multi-Accounts option Share Disseminate your content everywhere, instantly Statistics Analyze your audience's behavior Subscribers Share exclusive content with your subscribers Accessibility Publish accessible content Link detection Identify, activate and import your links automa
AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement March 2, 2021 | 8 min read Twitter LinkedIn Facebook Email Print AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (“LyGene … ed U.S. Food and Drug Administration clearance for its Investigational New Drug application to conduct a Phase 2a clinical trial on the safety, tolerability, and efficacy of its lead cell therapy for patients with end-stage liver disease, with study initiation planned for 2021. The combined company’s pipeline would also include thymus, pancreas, and kidney regeneration, in addition to the existing AgeX assets, including UniverCyte™, which uses the HLA-G gene to potentially co … geneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes wi … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026  
LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busines … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology October 21, 2019 | 3 min read Twitter LinkedIn Facebook Email Print Funds will support a Phase 2a clinical trial for patients with end stage liver disease in 2020 PITTSBURGH , Oc … te financing of convertible notes from Juvenescence , Ltd. and Longevity Vision Fund. Their technology uses lymph nodes as bioreactors to regrow functioning organs within a patient's own body. This financing will enable LyGenesis's lead program in liver regeneration to transition into clinical development, beginning with a Phase 2a clinical trial for patients with end stage liver disease in 2020. "We have advanced our liver regeneration program through preclinical trials and … r of LyGenesis's Board of Directors. Sergey Young , founder of Longevity Vision Fund, said "The ability to regenerate functioning ectopic organs was science fiction just a few short years ago. The progress of LyGenesis's technology is emblematic of the rapid advances we are witnessing as biotechnology transitions from bench research, to preclinical models, and now into the clinic." About LyGenesis, Inc. LyGenesis is a biotechnology company with an organ regeneration technolog … of aging. To learn more, please visit juvenescence.ltd . About Longevity Vision Fund Longevity Vision Fund is a $100M life extension-focused investment fund dedicated to making longevity affordable and accessible to all. Founded by Sergey Young , the fund accelerates breakthroughs in longevity by investing in start-ups and companies that dev
LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Develo … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease April 2, 2024 | 4 min read Twitter LinkedIn Facebook Email Print LyGenesis announced today that the first patient has been dos … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
LyGenesis Closes $3 Million Series A Financing to Advance Its Organ Regeneration Technology to the Clinic - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country LyGenesis Closes $3 Million Series A Financing to Advance Its Organ Regeneration Technology to the Clinic May 9, 2018 | 4 min read Twitter LinkedIn Facebook Email Print Groundbreaking technology regrows organs inside a patient’s own lymph nodes PITTSBURGH, May 9, 2018 /PRNewswire/ -- LyGenesis, Inc., a bio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
LyGenesis - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Cor … aised $27.8M in funding from investors like Prime Movers Lab , Longevity Vision Fund and Juvenescence . The company has 161 active competitors, including 54 funded and 48 that have exited . Its top competitor s include companies like Nimbus Therapeutics , Intercept Pharmaceuticals and Madrigal Pharmaceuticals . Company Details LyGenesis is developing regenerative medicines for the treatment of liver disorders. The company is developing organ regeneration technology using pati … 5182656 9913368 Oct 21, 2019 8603405 Series A 8751821 5416035 Longevity Vision Fund Juvenescence Access funding benchmarks and valuations. Sign up today! View details of LyGenesis 's funding rounds and investors LyGenesis' founders and board of directors Founder? Claim Profile The founders of LyGenesis are Michael Hufford and Paulo Fontes . Here are the details of LyGenesis' key team members: Michael Hufford : Co-Founder of LyGenesis . Paulo Fontes : Co-Founde … lic diseases $83M Zhejiang Private Enterprise United Investment , BioVeda China Fund ... & 7 others 63/100 7th Ochre Bio 2019 , Oxford ( United Kingdom ) , Series A Developer of ribonucleic acid therapies for treating chronic liver diseases $39.7M Khosla Ventures , Y Combinator & 21 others 62/100 8th Enlivex Pharmaceuticals 2005 , Jerusalem ( Israel ) , Public Developer of autologous and allogeneic cell immunotherapy therapy treatments $7M Pontifax , Hadasit & 2 o … Developer of regenerative treatment for liver disorders $27.8M Longevity Vision Fund , Prime Movers Lab & 1 others 40/100 Get insights and benchmarks for competitors of 2M+ companies! Sign up today! Looking for more details on LyGenesis 's competitors? Click here to see the top ones LyGenesis's Investments and acquisitions LyGenesis
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
Universe Science technology Aliens UFO🌟👽 | A groundbreaking experimental treatment from LyGenesis aims to cultivate miniature livers within patients’ lymph nodes
Michael Hufford - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance F … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung … ogy from the University of Pittsburgh before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School. He is the author of more than 100 scientific publications, presentations, and OpEds, with multiple issued and pending patents. Sessions 22-Jun-2026 2:45 PM – 3:00 PM Theater 1 LyGenesis Inc. BIO DOUBLE HELIX SPONSORS Our sponsors help support BIO's mission to support and advocate for the biotechnology industry. Loading BIO
LyGenesis Inc. - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FA … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
What Is A Longevity Biotechnology Company? Sign Up For Newsletters Games Share a News Tip Featured Featured Breaking News White House Watch Daily Cover Stories Making It Their Way: Six TikTok Creators On Finding A High-Quality Content Strategy That Pays Off | Paid Program The Hidden Tax On Enterprise AI: 1 In 5 Workers Lose A Full Day Every Week | Paid Program Silicon & Steel Editorial Video Series Turning Pressure Into Progress For Your Small Business | Paid Program Uniting To Advance Blood Cancer Research | Paid Program The Enterprise AI Shortcut: Why Co-Innovation Is Setting A New Speed … scence, Life Biosciences, Longevity Biotechnology Association, Longevity Vision Fund, Lygenesis, Oviva Therapeutics, Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School, Rejuveron, Retro Biosciences, and Tornado Therapeutics. Picture of the screen showing a research paper titled "Defining a longevity biotechnology company", Nature Biotechnology, June 2023 Alex Zhavoronkov, PhD This perspective paper underscores the importance of defining lon … vides additional insights, emphasizing that investors should consider "the application of the technology to a clear disease indication today, allowing the medicine to reach the market after being tested for safety and efficacy, and the ability of the intervention to not only treat but also prevent disease." As the longevity biotechnology landscape continues to expand, it's crucial for stakeholders, from investors to researchers, to have a clear understanding of
Hacking Humanity: How technology can save your health and your life Forever.AI: AI, Robotics, Quantum, Longevity, Cryonics & BCI Subscribe Sign in Hacking Humanity: How technology can save your health and your life New longevity book by Lara Lewington (BBC Journalist, television presenter) Alex Zhavoronkov, PhD Jul 10, 2025 15 3 Share Thirteen years have flown by since I published The Ageless Generation . That book warned of the coming “Silver Tsunami” and explored early longevity science and aging economics, but in truth, my most actionable advice boiled down to what I call “Do What Your … diting: CRISPR is explained not as a far-off concept but through its real-world application in the first FDA-approved treatment for sickle-cell disease, grounding the revolutionary in the tangible. She also explores one-off gene-editing treatments to permanently lower cholesterol by deactivating the PCSK9 gene. Advanced Organ Engineering: The book delves into "organs-on-a-chip" technology and the work of companies like LyGenesis , which is trialing methods to regrow
Inspire Longevity | ARDD 2024 Main Past events ARDD 2025 ARDD 2024 XPRIZE Healthspan Team Summit 2024 ARDD 2023 ARDD 2022 About Speakers Speakers 2026 Speakers 2025 Speakers 2024 Speakers 2023 Speakers 2022 Program Main Track Longevity Medicine Track Emerging Science & Technologies Workshop Physics in Aging Biology Startup Pitch Replacement in Aging Workshop Molecular Nutrition Workshop ARDD Tracks Sponsorship Sponsorship Brochure Sponsors 2025 Sponsors 2024 Sponsors 2023 Sponsors 2022 Media Scam Warning Photos Videos Media Kit Photos 2025 Photos 2024 Photos 2023 Photo … ict media bias and identify fake news. It is amazing to have the opportunity to apply my interests towards big problems that impact society. Nina Khera I'm a teenager who is interested in preventing brain aging-related diseases. I have worked with both companies such as Alio Medical, Lygenesis, and Rubedo Life Sciences and labs such as the Gladyshev and Adams labs on data science and biology-based projects. I am also currently working on a startup, Biotein, that has raised $6 … am a 16 year old student at Sevenoaks School in the UK. My interest lies in the application of mathematical modelling and statistics in longevity research. I am also interested in private equity and venture capital, so I would like to get involved with investment in the longevity industry. I have had experience in insurance where I learned how to use probability and statistics in finance, so I would like to apply this knowledge in the longevity industry. Currently I am workin
Biotech – Page 2 – Bio Capital Weekly Skip to content Bio Capital Weekly Facebook LinkedIn Twitter Instagram Menu Home About Contact Tag: Biotech A Weekly Recap of Deals in Life Sciences: June 4-June 10, 2018 The week in numbers (the total value of the operations is shown in parenthesis): Angels, VC, PE, CVC deals: 20 ($707.4M) Asset acquisition: 1 ($2.7B) Debt financing: 1 ($20.5M) Divestures: N/A Funds: 4 ($1.6B) Grants awarded: 1 ($3M) IPOs: 1 ($75M) IPO filings: 2 ($242M) IPO pricing: 5 ($492.76M – $563.18M) Licensing/Partnerships: 5 ($1.79B) M&As: 5 (>$889M) … Investors pre-IPO: Kadmon Corporation (16.9%), Perceptive Life Sciences Master Fund (15.9%), Adena Estate (8.4%), Alexandria Equities No. 7 (7.9%), Robin Ali (5.2%) Stock Exchange: Nasdaq Proposed Symbol: MGTX Underwriters: BofA Merrill Lynch, Barclays, Evercore ISI, Chardan Sources: SEC Form S-1 Axios Deal: IPO filing Company: Tricida (South San Francisco, CA) CEO: Gerrit Klaerner, PhD Area: Chronic Kidney Disease Stage: Clinical Capital Planned to Raise: $150M Number of sh … jor Investors pre-IPO: Paul B. Manning (58.4%), Perceptive Life Sciences Master Fund (12.1%), OrbiMed Private Investments VI (6.4%) Capital raised pre-IPO: $257M Stock Exchange: Nasdaq Proposed Symbol: VRCA Underwriters: BofA Merrill Lynch, Jefferies, and Cowen Sources: SEC Form S-1/A Deal: IPO Pricing Company: Autolus Therapeutics (London, UK) CEO: Christian Itin, PhD Area: Chimeric Antigen Receptor (CAR) T cell therapies Stage: Clinical Capital Planned to Raise: $134.76M &# … ics (8.4%), Cowen Healthcare Investments II (7.5%), EcoR1 Capital (5.5%), Omega Fund IV (5.2%) Capital raised pre-IPO: $78.3M Stock Exchange: Nasdaq Proposed Symbol: KZR Underwriters: Jefferies, Cowen, Wells Fargo Securities, William Blair Sources: SEC Form S-1/A Deal: IPO Pricing Company: Magenta Therapeutics (Cambridge, MA) CEO: Jason Gardner, DPhil Area: Bone marrow transplantation therapy Stage: Clinical Capital Planned to Raise: $107.3M – $122.7M Number of shares o … Raised: $18.5M Total Capital Raised: N/A Investors: Orbimed Asia and AnlongMed Fund Sources: Crunchbase BioCentury Deal: Series B financing Company: ENYO Pharma (Lyon, France) CEO: Jacky Vonderscher, PhD Area: Small molecule therapeutics in various therapeutic areas Stage: Clinical Capital Raised: €40M ($53.5M) Total Capital Raised: €64.5M ($75.
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architecture and Construction Residential Real … geneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes wi
��[��H�%:��VwV�%��:*k�\�P�BR�U��e������0��p?�(z&5�{�1wy��JHݕ�r�0���y��7��)M�VV���0x���PYdb����?|x���/��*�JA���OV�� 6e�?��v�����)ֽa�?���w��G��@g��Y�������%�$�����۞������ ������Y��})�+� ;U\���$�������_�Ϋe�����m�ő���?�ׯ߉z��z�ʔ����Ou�S��~,��ej�?��~0�����I�����o���o����jU���,����oz���� m ]��L�^��7=^�/z�����X� 7����Z J��L�ā,�HeeA=r��*3� �(u�l`�h��������bY�Rq;�� 3E*� 2UV�x��c�l��9��`��v�]�{���:�߾}��ޫ}��#�H�+)>`t�=�N�����= h����� �iEjl)V25����1� ���z$6� +�8�p� �LF��V�~���bYG��ɒ�h�I�F\)� +WJ��I/�'�G��� �a�FJ���뵢����Ufs��X,����* ��X'fI ��[�.���ճ`
BRIEF—AgeX Therapeutics and LyGenesis call off merger | The Pharmaletter Thursday 25 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vasc
Report — KPsphere AI Signal Intelligence ESC ↑ ↓ navigate ↵ open ESC close Home Briefings Research Weekly Sectors Products Videos Stats About Search / Subscribe ← Back to Archive Copy Link Loading report... Continue Reading Related Research © 2026 KPsphere. All rights reserved. AI Signal Intelligence.
Business Of Biotech Mon, 22 Jun 2026 06:00:03 -0400 https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast en © 2026 Business Of Biotech yes c77ff782-6b54-5e46-8d1b-8c94bf2bd494 Ben Comer episodic false The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each ep … Exsilio charted its way to an $82 million Series A c o-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in t … Exsilio charted its way to an $82 million Series A c o-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in t … rkets healthcare investor on Wall Street for well more than a decade. Her hedge fund experience followed the Human Frontiers/Howard Hughes postdoctoral fellowship at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center that was preceded by an Oxford Ph.D. in Molecular Genetics. Since 2015, she's been drawing from her immersion in both the business and science disciplines as President & CEO at Meira GTx. On this episode of the Business of Biot … rkets healthcare investor on Wall Street for well more than a decade. Her hedge fund experience followed the Human Frontiers/Howard Hughes postdoctoral fellowship at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center that was preceded by an Oxford Ph.D. in Molecular Genetics. Since 2015, she's been drawing from her
An Update on Progress at Tissue Engineering Company Lygenesis – Fight Aging! Home FAQ Fund Research Services Investing Therapies Newsletter Archives Press Room Resources About Fight Aging! Do you want to live a longer life in good health? Simple practices can make some difference, such as exercise or calorie restriction. But over the long haul all that really matters is progress in medicine: building new classes of therapy to repair and reverse the known root causes of aging. The sooner these treatments arrive, the more lives will be saved. Find out how to help » January 4th, 2021 … od and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application. Under the IND, LyGenesis will be conducting a Phase 2a study on the safety, tolerability, and efficacy of its first-in-class novel cell therapy for patients with end stage liver disease (ESLD) . In addition, LyGenesis announced it has just completed over $11 million in private financing of convertible notes led by Juvenescence Ltd. and Longevity Vision Fund . Proceeds will be used to … Living Longer Read the Fight Aging! FAQ Sign up for the Fight Aging! Newsletter Fund Meaningful Aging Research Services Longevity Industry Consulting How to Start a Longevity Biotech Company The Root Causes of Aging Aging is Caused by Damage Accumulating Cross-Links Buildup of Amyloid Between Cells The Failing Adaptive Immune System The Failing Innate Immune System Declining Lysosomal Function Mitochondrial DNA Damage Nuclear DNA Damage Buildup of Senescent Cells Archives and … Feed RSS Comments Feed Using the Fight Aging! Content Feeds Required Reading A Proposal to Accelerate Progress Calorie Restriction and Longevity Cryonics, the Necessary Backup Plan How to Argue for Longevity Science The Odds of Human Longevity Mutations The Need For Activism and Advocacy Nuanced Opposition to the FDA Potential Gene Therapy Targets Predicting the First Rejuvenation Therapies Self-Experiment to Fight Aging! SENS: Bringing an End to Aging Stem Cells and Regener … ht Aging!. Home | FAQ | Fund Research | Services | Investing | Therapies | Newsletter | Archives | Press Room 
Nuove piattaforme per la rigenerazione di organi a partire da cellule staminali/progenitori - Fondazione RI.MED skip to Main Content Menu LA FONDAZIONE STORIA SOCI FONDATORI CLUSTER Ri.MED-ISMETT-UPMC SEDI OPERATIVE ORGANI DIRETTIVI FACT SHEET GEP CONTATTI RICERCA AREE TERAPEUTICHE PROGETTI DI RICERCA FACILITIES GRUPPI DI RICERCA PEOPLE PUBBLICAZIONI HOST INSTITUTION GRANTS TECH TRANSFER COLLABORAZIONI BREVETTI OPPORTUNITÀ HR-TIROCINI HR-LAVORA CON NOI BANDI DI GARA SPONSORSHIP COMUNICAZIONE DIVULGAZIONE EVENTI SCIENTIFICI NEWS E COMUNICATI STAMPA RASSEGNA STAMPA DOWNLOAD PRESS KIT NEWSLETTER
Company Stories K-L Carl Nelson Consulting phone/ fax 202-331-9757 [email protected] SBIR for high tech innovators home News Do SBIR FAQs Links Archives Company Stories K-L Stories that earlier appeared in Nelson's News Note 1: Carl Nelson Consulting, Inc is not an investment adviser and may hold a financial interest or client relationship in companies discussed. (Note 2: Carl Nelson Consulting does not endorse these companies or organizations or their activities.) Looking for other older stories? Visit the archives K2M .... K2 Therapeutics .... KAER Biotherapeutics … c 28, 2022] announced that [FDA] has accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome (MSC-S), initially in development for the treatment of persistent corneal epithelial defect (PCED) . [company press release, Dec 27, 2022] Kala Pharmaceuticals (Waltham, MA; $400K SBIR) up 23% [Nov 9, 2022] reported quarterly financials Kala Pharmaceuticals (Watertowwn, MA; $400K SBIR) down 19%[O … rack Phase I/II STTR from the National Heart Blood and Lung Institute and a $3M grant through the Congressionally-Directed Medical Research Program (CDMRP) from [DOD]. [crunchbase.com, Jun 12, 18] developing ErythroMer novel blood substitute composed of a patented nanobialys nanoparticle . [Washington University website] Kalon Biotherapeutics (College Station, TX) Kalon Biotherapeutics (College Station, TX; no SBIR) biotech manufacturer that specializes in vaccines, has been … ynth Biotechnologies. ... received funding from the state's Emerging Technology Fund, was launched in 2011 out of the Texas A&M University system. ... will now be named FujiFilm Diosynth Biotechnology Texas LLC, has specialized in manufacturing vaccines for biotechnology companies, most notably GlaxoSmithKline, [CEO Andrew] Strong said. [Joe Martin, Houston Business Journal, Dec 18, 14] KalVista Pharmaceuticals) KalVista Pharmaceuticals (no SBIR) … ckage are a $1.25 million forgivable loan from Kenosha County, and a $4 million grant from the City of Kenosha [Rick Romell, Milwaukee Journal Sentinel, Jun 25, 15] Kensey-Nash Kensey Nash up 32% [May 3, 12] said it will be acquired for about $360 million by Royal DSM, a Dutch manufacturer with operations in the pha
PLSA Case Study | LyGenesis About PLSA Company Directory Spotlights News & Resources events Careers Contact Company Spotlight LyGenesis LyGenesis Is Growing Organs in Lymph Nodes—and Rethinking the Future of Transplantation With organ shortages claiming thousands of lives each year, LyGenesis is working to rewrite the rules of transplantation—by growing organs inside a patient’s own body. The Pittsburgh-based company is pioneering a novel approach to cell therapy that use a patient’s lymph nodes as natural bioreactors to grow fully functioning organs within the body. Their lead program, no
2026 Attendees | LSX Congress USA You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Life Science Executive Partnering Congress Sept 23-24, Forums Sept 22, 2026 BCEC, Boston, USA Home home Agenda expand_more Day 0 Day 1 Day 2 Speakers Showcase expand_more Apply … nvestor Alykomed Global Solutions LLC Investor Ambrosia Ventures Investor Amoon Fund Investor Anada Scientific C-Level / Founder / Chairman ANAMAX Innovation Investor Angelini Ventures Investor ANGELINI VENTURES Investor Angelini Ventures Investor Aperture Therapeutics Inc C-Level / Founder / Chairman Apollo Health Ventures Investor Arivin therapeutics C-Level / Founder / Chairman Artax Biopharma C-Level / Founder / Chairman Artiva Biotherapeutics Director / Management ASKA P … r Ingelheim Investor Boehringer Ingelheim SVP / VP / Head Bold Longevity Growth Fund Investor Boston Harbor Angels SVP / VP / Head Boundless Health Partners Investor Boyd Consultants Director / Management brain feed Therapeutics Ltd C-Level / Founder / Chairman Breslin Ag Investor Bristol Myers Squibb Director / Management Broadview Ventures Investor Brothers & Partners Europe Investor Brown Rudnick Director / Management Brown Rudnick Investor Brown Rudnick LLP Other Camb … rsity of Kentucky Director / Management Chiesi Ventures Investor Chugai Venture Fund, LLC Investor Chugai Venture Fund, LLC Investor Chugai Venture Fund, LLC Investor Cleaved Diagnostics C-Level / Founder / Chairman Click Therapeutics C-Level / Founder / Chairman CMS Director / Management CMS Cameron McKenna Nabarro Olswang LLP Other Concept Bio Investor Conscious Capital, Inc. Investor Consun Pharmaceutical Group Director / Management Cornucopian Capital Investor Cornucopian … / Founder / Chairman CR Ventures Investor CSL SVP / VP / Head CTI Life Sciences Fund Investor Cukierman & Co. Life Sciences Other CureDuchenne Investor Cytotheryx Inc C-Level / Founder / Chairman Cytotheryx, Inc. C-Level / Founder / Chairman Daejoong Life Science Investor Danaher Investor Davis Polk & Wardwell Director / Management DeepWo
About Us | Lygenesis Skip To Main Content toggle menu About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs. Instead of one donor organ treating one patient, LyGenesis’ technology enables one donor organ to treat dozens of patients. Instead of major surgery, LyGenesis uses outpatient endoscopic ultrasound for transplantation of its cell therapy, which enables cells to engraft, proliferate, and become a functioning ectopic organ. LyGenes
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Data and Safety Monitoring Board Approves LyGenesis's Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration | Lygenesis Skip To Main Content toggle menu Investors & Media Company Overview View All LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder. Press Release Data
From Technology Developed at the McGowan Institute, LyGenesis Closes $3 Million Series A Financing to Advance Its Organ Regeneration Technology to the Clinic – Regenerative Medicine at the McGowan Institute Skip to content Search for: PITT HEALTH SCIENCES UPMC Search for: Toggle Navigation Home About Us Welcome Mission, Vision, and Overview What Is Regenerative Medicine? Faculty/Sr. Staff Bios Executive Committee Leadership Staff Contact Us Clinical Site Our Research Programs McGowan Partnerships Laboratories Find Clinical Trials Research Pillars Matrix Our Technologies Professional Deve
LSFSW Company Presentations | Life Sciences PA Close Who We Are About Us Meet Our Team Board of Directors Membership Membership Benefits Become a Member Member Directory Member News Advocacy The Voice for PA’s Life Sciences Policy Priorities Our Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Member Login Industry News Contact Us Who We Are … Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Life Sciences Future SW Powered By: 2026 Company Presenters Company Presentations The company presentations features two stages – Entrepreneur Arena and Startup Stadium … they need to succeed. $ Life Sciences Events Events Calendar Overview of Events Submit Your Event Sponsorship & Volunteer Opportunities Life Sciences Future Photo Gallery The Voice for PA's Life Sciences Through public policy advocacy in Harrisburg and Washington, D.C., Life Sciences PA serves as the voice for more than 960 member organizations across Pennsylvania that are critical to improving patient care, improving health globally, and to the economic growth of the Com
Our Science | Lygenesis Skip To Main Content toggle menu Our Science Revolutionary Biotechnology Our allogeneic cell therapies leverage the biology of the lymph node to engraft, proliferate, and form functional ectopic organs that recapitulate the native organ's function. LyGenesis uses the lymph node's evolutionary function - to serve as an efficient and rapid bioreactor for T-cell to help fight infection - to help vascularize our allogenic cell therapies, a key barrier to the successful clinical application of many other cell therapies. Using donated but not transplanted organs, our therapie
LyGenesis, Inc. | Life Sciences PA Close Who We Are About Us Meet Our Team Board of Directors Membership Membership Benefits Become a Member Member Directory Member News Advocacy The Voice for PA’s Life Sciences Policy Priorities Our Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Member Login Industry News Contact Us Who We Are About Us Mee … Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters LyGenesis, Inc. Back to Search LyGenesis, Inc. Categories Biotechnology www.lygenesis.com About LyGenesis is a clinical-stage biotechnology company whose cell therapies use p … ism. Privately held with investment support from Juvenescence, Longevity Vision Fund, and other investors, LyGenesis is headquartered in Pittsburgh, Pennsylvania. Share × for each option that currently exists--> Print Facebook LinkedIn X Pinterest Close Powered By GrowthZone Get Updates from LSPA Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more! Success! First Name Last Name Email Subscribe L … they need to succeed. $ Life Sciences Events Events Calendar Overview of Events Submit Your Event Sponsorship & Volunteer Opportunities Life Sciences Future Photo Gallery The Voice for PA's Life Sciences Through public policy advocacy in Harrisburg and Washington, D.C., Life Sciences PA serves as the voice for more than 960 member organizations across Pennsylvania that are critical to improving patient care, improving health globally, and to the economic growth of the Com
About Us | Lygenesis Skip To Main Content toggle menu About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's lymph nodes into bioreactors capable of growing functioning ectopic organs. Instead of one donor organ treating one patient, LyGenesis’ technology enables one donor organ to treat dozens of patients. Instead of major surgery, LyGenesis uses outpatient endoscopic ultrasound for transplantation of its cell therapy, which enables cells to engraft, proliferate, and become a functioning ectopic organ. LyGenes
Other news to note for March 2, 2021 | 2021-03-02 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-ener
LyGenesis, Inc. | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies LyGenesis, Inc. LyGenesis is a clinical-stage biotechnology company that transforms a patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs. Their innovative cell therapies aim to address large unmet medical needs such as end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorders. They utilize outpatient endoscopic ultrasound procedures to engraft cells, which reduces medical risks and costs